At the 44th Annual J.P. Morgan Healthcare Conference, Executive Vice President and CFO Scott Reents emphasized two core objectives for 2026: delivering strong operational performance and advancing the clinical pipeline. Reents reflected on the company’s successful navigation of the HUMIRA loss of exclusivity in 2023, noting that AbbVie outperformed internal volume and revenue targets for its immunology portfolio by more than 15% in the first full year post-LOE. He indicated that full-year 2025 guidance—which AbbVie will report in late January—will reflect double-digit adjusted operating margin expansion and up to 5% year-over-year growth in total net revenues. The leadership team remains committed to maintaining at least a 25% research and development reinvestment rate while targeting pipeline milestones in oncology, neuroscience and women’s health.

AbbVie confirmed plans to build out its presence in the rapidly growing obesity segment by integrating the weight-loss therapy it licensed from Danish biotech Gubra in mid-2025. The agreement grants AbbVie exclusive global rights to the subcutaneous GLP-1 analogue, which demonstrated mean body-weight reductions of 12.4% in Phase II trials involving 450 patients over 32 weeks. The drug is on track for a rolling submission to the FDA in the second quarter of 2026, with European regulatory filings to follow by year-end. AbbVie projects that, if approved, the new obesity asset could address a global addressable market valued at more than $25 billion by 2030, complementing its existing metabolic franchise and supporting an additional 3–5 percentage points of top-line growth by 2028.